Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Investor Conference
Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company, announced its participation in the H.C. Wainwright BioConnect Investor Conference on May 2, 2023, at the Nasdaq Headquarters in New York City. The session, featuring President and CEO Adrian Gottschalk, will take place at 1:30 p.m. ET. Foghorn is focused on developing innovative medicines that address abnormal gene expression, particularly in oncology, through its Gene Traffic Control platform. A webcast of the panel discussion will be available on Foghorn's website for 30 days following the event. For more details, visit www.foghorntx.com.
- None.
- None.
CAMBRIDGE, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that it will participate at the H.C. Wainwright BioConnect Investor Conference, which is taking place May 2, 2023, at the Nasdaq Headquarters in New York City. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
Fireside chat date and time: Tuesday, May 2, 2023, 1:30 p.m. ET
Foghorn Presenter: Adrian Gottschalk, President and Chief Executive Officer
Please find a link to the panel here.
A webcast of the panel can also be accessed under “Events & Presentations” in the Investors section of Foghorn’s website, www.foghorntx.com, and will be available for up to 30 days.
About Foghorn Therapeutics
Foghorn® Therapeutics Inc. is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. Foghorn is developing multiple product candidates in oncology. For more information about Foghorn, visit our website at www.foghorntx.com, and follow us on Twitter and LinkedIn.
Contact:
Ben Strain, Foghorn Therapeutics Inc. (Media and Investors)
bstrain@foghorntx.com
Karin Hellsvik, Foghorn Therapeutics Inc. (Media)
khellsvik@foghorntx.com
Michael Lampe, ScientPR (Media)
michael@scientpr.com
Hans Vitzthum, LifeSci Advisors (Investors)
hans@lifesciadvisors.com
FAQ
What is Foghorn Therapeutics participating in on May 2, 2023?
Who will represent Foghorn Therapeutics at the conference?
What time is Foghorn's presentation at the conference?
Where can I watch Foghorn Therapeutics' presentation?
What platform does Foghorn Therapeutics use for drug development?
